File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: LINE-1 hypomethylation is associated with poor risperidone response in a first episode of psychosis cohort

TitleLINE-1 hypomethylation is associated with poor risperidone response in a first episode of psychosis cohort
Authors
KeywordsLINE-1
treatment response
psychosis
schizophrenia
DNA methylation
risperidone
Issue Date2020
Citation
Epigenomics, 2020, v. 12, n. 12, p. 1041-1051 How to Cite?
AbstractAim: We investigated the DNA methylation profile over LINE-1 in antipsychotic-naive, first-episode psychosis-patients (n = 69) before and after 2 months of risperidone treatment and in healthy controls (n = 62). Materials & methods: Patients were evaluated using standardized scales and classified as responders and nonresponders. DNA from blood was bisulfite converted and LINE-1 fragments were amplified and pyrosequencing was performed. Results: Lower LINE-1 methylation was observed in antipsychotic-naive first-episode psychosis patients than in healthy controls. Lower DNA methylation levels before treatment were associated with poor risperidone responses. A positive correlation was observed between LINE-1 methylation levels and positive symptoms response. Conclusion: Our study brings new insight regarding how epigenomic studies and clinical correlation studies can supplement psychosis treatment.
Persistent Identifierhttp://hdl.handle.net/10722/288829
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMarques, Diogo Ferri-
dc.contributor.authorOta, Vanessa Kiyomi-
dc.contributor.authorSantoro, Marcos Leite-
dc.contributor.authorTalarico, Fernanda-
dc.contributor.authorCosta, Giovany Oliveira-
dc.contributor.authorSpindola, Leticia Maria-
dc.contributor.authorCogo-Moreira, Hugo-
dc.contributor.authorCarvalho, Carolina Muniz-
dc.contributor.authorXavier, Gabriela-
dc.contributor.authorCavalcante, Daniel Azevedo-
dc.contributor.authorGadelha, Ary-
dc.contributor.authorNoto, Cristiano-
dc.contributor.authorCordeiro, Quirino-
dc.contributor.authorBressan, Rodrigo Affonseca-
dc.contributor.authorMoretti, Patricia Natalia-
dc.contributor.authorBelangero, Sintia Iole-
dc.date.accessioned2020-10-12T08:05:59Z-
dc.date.available2020-10-12T08:05:59Z-
dc.date.issued2020-
dc.identifier.citationEpigenomics, 2020, v. 12, n. 12, p. 1041-1051-
dc.identifier.urihttp://hdl.handle.net/10722/288829-
dc.description.abstractAim: We investigated the DNA methylation profile over LINE-1 in antipsychotic-naive, first-episode psychosis-patients (n = 69) before and after 2 months of risperidone treatment and in healthy controls (n = 62). Materials & methods: Patients were evaluated using standardized scales and classified as responders and nonresponders. DNA from blood was bisulfite converted and LINE-1 fragments were amplified and pyrosequencing was performed. Results: Lower LINE-1 methylation was observed in antipsychotic-naive first-episode psychosis patients than in healthy controls. Lower DNA methylation levels before treatment were associated with poor risperidone responses. A positive correlation was observed between LINE-1 methylation levels and positive symptoms response. Conclusion: Our study brings new insight regarding how epigenomic studies and clinical correlation studies can supplement psychosis treatment.-
dc.languageeng-
dc.relation.ispartofEpigenomics-
dc.subjectLINE-1-
dc.subjecttreatment response-
dc.subjectpsychosis-
dc.subjectschizophrenia-
dc.subjectDNA methylation-
dc.subjectrisperidone-
dc.titleLINE-1 hypomethylation is associated with poor risperidone response in a first episode of psychosis cohort-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2217/epi-2019-0350-
dc.identifier.pmid32657132-
dc.identifier.scopuseid_2-s2.0-85090078770-
dc.identifier.volume12-
dc.identifier.issue12-
dc.identifier.spage1041-
dc.identifier.epage1051-
dc.identifier.eissn1750-192X-
dc.identifier.isiWOS:000562789800001-
dc.identifier.issnl1750-192X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats